CD226 and neoplasm: We analyzed bulk RNA-seq from NSCLC tumor samples from three randomized clinical trials with atezolizumab and assessed how gene expression of CD226, PDCD1 (encoding PD-1), and TIGIT associated with clinical outcomes.